Literature DB >> 19326143

B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder?

Petra Richter1, Markus Tost, Marcus Franz, Annelore Altendorf-Hofmann, Kerstin Junker, Laura Borsi, Dario Neri, Hartwig Kosmehl, Heiko Wunderlich, Alexander Berndt.   

Abstract

PURPOSE: Surveillance of urothelial carcinoma of the urinary bladder (UBC) patients with respect to tumour recurrence and invasiveness is crucial for therapy and prognosis. Therefore, evaluation of non-invasive methods to monitor tumour progression is of high clinical interest. The study was aimed at investigating urinary concentrations of tenascin-C splicing domains for their value as tumour surveillance markers.
METHODS: Urinary concentration of B and C domain containing tenascin-C (Tn-C) was analysed by ELISA technology in 104 UBC patients, 11 patients with cystitis and 15 healthy donors as control. The investigation was supplemented by Tn-C immunohistochemistry and Western blotting.
RESULTS: A statistically significant increase in urinary concentrations of both Tn-C B and C domain with tumour progression could be evidenced. A concordant tumour-associated enhanced protein deposition in the carcinoma stroma could be demonstrated by immunohistochemistry in invasive UBC. Western blotting reveals proteolytic fragmentation of urinary Tn-C.
CONCLUSIONS: In summary, detection of Tn-C splicing domains in urine is suggested as a marker for the surveillance of UBC recurrence and invasiveness.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19326143     DOI: 10.1007/s00432-009-0576-6

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  38 in total

1.  Human tenascin-C: identification of a novel type III repeat in oral cancer and of novel splice variants in normal, malignant and reactive oral mucosae.

Authors:  A J Mighell; J Thompson; W J Hume; A F Markham; P A Robinson
Journal:  Int J Cancer       Date:  1997-07-17       Impact factor: 7.396

2.  Enzyme immunoassay for quantification of tenascin in biologic samples.

Authors:  S Ylätupa; P Mertaniemi; C Haglund; P Partanen
Journal:  Clin Biochem       Date:  1995-06       Impact factor: 3.281

3.  Fetal fibronectin: a new screening-marker for bladder cancer?

Authors:  H Wunderlich; O Reichelt; D H Zermann; J Schubert; A Berndt; H Kosmehl
Journal:  Oncol Rep       Date:  2001 May-Jun       Impact factor: 3.906

4.  Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas.

Authors:  E Ozdemir; Y Kakehi; H Okuno; O Yoshida
Journal:  J Urol       Date:  1999-04       Impact factor: 7.450

5.  Tenascin C and annexin II expression in the process of pancreatic carcinogenesis.

Authors:  I Esposito; R Penzel; M Chaib-Harrireche; U Barcena; F Bergmann; S Riedl; H Kayed; N Giese; J Kleeff; H Friess; P Schirmacher
Journal:  J Pathol       Date:  2006-04       Impact factor: 7.996

6.  Matrix metalloproteinases (MMPs) in bladder cancer: the induction of MMP9 by epidermal growth factor and its detection in urine.

Authors:  J E Nutt; G C Durkan; J K Mellon; J Lunec
Journal:  BJU Int       Date:  2003-01       Impact factor: 5.588

7.  Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues.

Authors:  L Borsi; B Carnemolla; G Nicolò; B Spina; G Tanara; L Zardi
Journal:  Int J Cancer       Date:  1992-11-11       Impact factor: 7.396

8.  Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin.

Authors:  Laura Borsi; Enrica Balza; Marco Bestagno; Patrizia Castellani; Barbara Carnemolla; Attila Biro; Alessandra Leprini; Jorge Sepulveda; Oscar Burrone; Dario Neri; Luciano Zardi
Journal:  Int J Cancer       Date:  2002-11-01       Impact factor: 7.396

9.  IIICS de novo glycosylated fibronectin as a marker for invasiveness in urothelial carcinoma of the urinary bladder (UBC).

Authors:  Petra Richter; Kerstin Junker; Marcus Franz; Angela Berndt; Christiane Geyer; Mieczyslaw Gajda; Hartwig Kosmehl; Alexander Berndt; Heiko Wunderlich
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-03       Impact factor: 4.553

10.  Tenascin-C inhibits extracellular matrix-dependent gene expression in mammary epithelial cells. Localization of active regions using recombinant tenascin fragments.

Authors:  P L Jones; N Boudreau; C A Myers; H P Erickson; M J Bissell
Journal:  J Cell Sci       Date:  1995-02       Impact factor: 5.285

View more
  8 in total

1.  Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-C splicing variants in human myocardial tissue of the right atrial auricle: implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies.

Authors:  Marcus Franz; Bernhard R Brehm; Petra Richter; Katja Gruen; Dario Neri; Hartwig Kosmehl; Khosro Hekmat; Andre Renner; Jan Gummert; Hans R Figulla; Alexander Berndt
Journal:  J Mol Histol       Date:  2010-03-16       Impact factor: 2.611

2.  A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies.

Authors:  Alexander Berndt; Robert Köllner; Petra Richter; Marcus Franz; Astrid Voigt; Angela Berndt; Laura Borsi; Raffaella Giavazzi; Dario Neri; Hartwig Kosmehl
Journal:  Histochem Cell Biol       Date:  2010-03-17       Impact factor: 4.304

Review 3.  Tenascin-C and carcinoma cell invasion in oral and urinary bladder cancer.

Authors:  Alexander Berndt; Petra Richter; Hartwig Kosmehl; Marcus Franz
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

Review 4.  Tenascin C in metastasis: A view from the invasive front.

Authors:  Camille M Lowy; Thordur Oskarsson
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

Review 5.  The Functional Role of Extracellular Matrix Proteins in Cancer.

Authors:  Nadezhda V Popova; Manfred Jücker
Journal:  Cancers (Basel)       Date:  2022-01-04       Impact factor: 6.639

6.  Tenascin-C promotes bladder cancer progression and its action depends on syndecan-4 and involves NF-κB signaling activation.

Authors:  Zhenfeng Guan; Yi Sun; Liang Mu; Yazhuo Jiang; Jinhai Fan
Journal:  BMC Cancer       Date:  2022-03-04       Impact factor: 4.430

7.  CYR61 as a potential biomarker for the preoperative identification of muscle-invasive bladder cancers.

Authors:  Huang Chen; Yu Liu; Chuanzhen Cao; Hao Xi; Wenting Chen; Wei Zheng; Xin Dong; Shan Zheng; Lin Li; Jianhui Ma; Yanning Gao; Jianzhong Shou
Journal:  Ann Transl Med       Date:  2021-05

Review 8.  Tenascin-C: Form versus function.

Authors:  Sean P Giblin; Kim S Midwood
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.